755results about How to "Easy to swallow" patented technology

A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

An electrical stimulation device and method for the treatment of dysphagia is disclosed. In a preferred embodiment, the electrical stimulation device includes one or more channels of electrodes each of which includes a first electrode positioned in electrical contact with tissue of a target region of a patient and a second electrode positioned in electrical contact with tissue of a posterior neck region or a posterior thoracic region of the patient. A series of electrical pulses are then applied to the patient through the one or more channels of electrodes in accordance with a procedure for treating dysphagia. The series of electrical pulses may comprise: a plurality of cycles of a biphasic sequential pulse train pattern; a plurality of cycles of a biphasic overlapping pulse train pattern; a plurality of cycles of a triphasic sequential pulse train pattern; a plurality of cycles of a triphasic overlapping pulse train pattern; a functional pulse train pattern; a low-frequency pulse train pattern; or a frequency-sequenced pulse burst train pattern. Various exemplary embodiments of the invention are disclosed.

A simple, non-invasive method and apparatus for treating oropharyngeal disorders provides electrical stimulation to the oropharyngeal region of a patient. The apparatus includes an electrical neuromuscular stimulator that includes a pulse generator for generating a series of electrical pulses and a processor coupled to the pulse generator for controlling its operation. The apparatus also includes a first electrode and a second electrode, each of which includes a snap eyelet having a connector to which a lead wire may be attached, a conductive film and an adhesive and conductive gel layer that is adapted to be attached to the skin of the patient. The apparatus also includes at least one lead wire for attachment of the electrodes to the pulse generator and at least one adhesively backed tape overlay for securing the first and second electrodes to the skin of the patient. According to the method, the electrodes are placed on the skin of the patient's throat, and the electrodes are secured to the skin of the patient's throat by applying at least one adhesively backed tape overlay to the patient's skin over at least a portion of each of the electrodes. The lead wires are attached to the connectors of the snap eyelets of the electrodes and to the output jack of the pulse generator, and a series of electrical pulses is generated using the pulse generator so as to apply the series of electrical pulses to the patient's throat using the electrodes.

A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.

Biologically inactive cushioning beads comprise at least one compressible cushioning component consisting essentially of a microcrystalline hydrocarbon wax or a natural wax, the said wax being at least 30% by weight of the biologically inactive cushioning beads. Such beads are useful for making solid shaped articles containing biologically active ingredients by compression.

The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.

The present invention is an oral solid pharmaceutical compositions for the treatment of kidney diseases and mineral bone disorder including a phosphate binder, a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, the invention further including a method for preparing the pharmaceutical compositions including the steps of granulating cinacalcet and / or sevelamer and / or vitamin D by one of a wet and a dry granulation process, each with at least one pharmaceutically acceptable excipient to form cinacalcet granules and / or sevelamer granules and / or vitamin D granules, mixing at least two of the cinacalcet granules, sevelamer granules and vitamin D granules to form a granules mixture and compressing the granules mixture to tablets or encapsulating the granules mixture into capsules or pulverizing the granules mixture into a dispersion powder.

The invention belongs to the technical field of medicine, and relates to a palbociclib gastric-floating tablet and a preparation method thereof. The palbociclib gastric-floating tablet comprises, by mass, 10%-30% of palbociclib, 20%-50% of hydroxypropyl methylcellulose, 20%-40% of bleaching auxiliaries, 2%-10% of foaming agents, 0%-25% of microcrystalline cellulose and 0.5%-3% of magnesium stearate. A dry granulating technology or a wet granulating technology can be used as the preparation technology. The palbociclib gastric-floating tablet is high in bioavailability, has a slow release tendency, and effectively lowers the total dosage. The palbociclib gastric-floating tablet and the preparation method thereof have the unique advantages that two different mechanisms are used for preparing the gastric-floating tablet, and accordingly the prepared tablet can keep floating in gastric juice by more than 10 hours and continuously release drugs in the hydrochloric acid solution with the pH being 1.2; the problem that the bioavailability is low due to the fact that drugs are extremely difficult to dissolve after the pH is higher than four is effectively solved; the medicine taking frequency is reduced; toxic and side effects are lightened; and the complaisance of a patient is effectively improved.

A method and system for training a patient to improve swallowing, for retraining jaw muscles and for holding or keeping the jaw in a correct bite position. All of this in-turn causing an improvement in posture. The system includes a combination of exercise and oral apparatus pieces or mouth-guards to retrain and balance the facial muscles and to develop a correct swallow. The mouth-guards of the present invention can improve biomechanical imbalance, posture and in turn athletic performance. A particular embodiment of an oral apparatus of the present invention includes top and bottom troughs for receiving top and bottom teeth into the apparatus. The troughs can be adapted to hold the upper canine teeth lower than the central and lateral incisor teeth and hold the upper teeth outside the lower teeth from the incisors to the molars. The apparatus can be pre-fabricated or custom made for a particular patient. Using heat moldable thermoplastics, some embodiments of the device can be formed in the patient's mouth after heating in hot water.

Provided is a compound having a superior acid secretion suppressive action, which shows an antiulcer activity and the like.A compound represented by the formula (I) or a salt thereof:wherein ring A is a saturated or unsaturated 5-membered heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom, the ring-constituting atoms X1 and X2 are the same or different and each is C or N, the ring-constituting atoms X3 and X4 are the same or different and each is C, N, 0 or S (provided that a pyrrole ring wherein X1 is N is excluded from ring A), and when the ring-constituting atom X3 or X4 is C or N, each ring-constituting atom optionally has substituent(s) selected from an optionally substituted alkyl, an acyl, an optionally substituted hydroxy, an optionally substituted mercapto, an optionally substituted amino, a halogen, a cyano and a nitro;R1 and R2 are each a cyclic group optionally having substituent(s); R3 and R4 are each H or alkyl, or R3 and R4 form, together with the adjacent N, an nitrogen-containing heterocycle; and Y is a spacer.

A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.